For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News

BREAKING NEWS
Source: Thailand Medical News  Dec 10, 2019  4 years, 11 months, 1 week, 6 days, 15 hours, 55 minutes ago

US FDA Approves Generics Versions Of Gilenya, A Multiple Sclerosis Drug

US FDA Approves Generics Versions Of Gilenya, A Multiple Sclerosis Drug
Source: Thailand Medical News  Dec 10, 2019  4 years, 11 months, 1 week, 6 days, 15 hours, 55 minutes ago
Pharma News

The American Regulator,  the Food and Drug Administration (FDA) has approved the first generic versions of Novartis multiple sclerosis drug Gilenya (fingolimod).


 
Applications for the generic fingolimod by HEC Pharm, Biocon and Sun Pharmaceutical Industries secured the FDA authorisation to treat adults with relapsing forms of multiple sclerosis.
 
Multiple sclerosis is an inflammatory, autoimmune disease that affects the central nervous system and disturbs communication between the brain and other body parts.
 
The condition is known to be one of the most common reasons behind neurological disability in young adults. Gilenya is a widely used oral drug to treat the condition.
 
The drug Gilenya is a disease-modifying therapy that acts on focal, as well as diffuse central nervous system damage caused by multiple sclerosis. According to Novartis, the drug recorded $3,341m in net sales last year, the highest among the company’s top 20 Innovative Medicines.
 
The drug currently has approvals in more than 90 countries for the treatment of relapsing forms of the disease and is licensed from Mitsubishi Tanabe Pharma,
 
Gilenya  is approved in the US for patients aged ten years and above. In the EU, the indication is for patients aged ten years and older with high disease activity even after receiving at least one disease-modifying agent and those with the fast-evolving severe relapsing-remitting disease.
 
 “Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA. Having access to affordable treatments is important for patients with conditions that require ongoing care. The FDA has a longstanding commitment to increasing patient access to lower-cost, high-quality generic medicines.” commented  Janet Woodcock, Director of  FDA Center for Drug Evaluation and Research, during a phone interview with Thailand Medical News.
 
The US regulator noted diarrhoea, headache, increased liver enzymes, back and abdominal pain, influenza, pain in the extremities and sinusitis as the most common side effects observed in Gilenya clinical trials.
 

MOST READ

Nov 05, 2024  19 days ago
Nikhil Prasad
Jul 25, 2024  4 months ago
Nikhil Prasad
Jul 24, 2024  4 months ago
Nikhil Prasad
Jun 10, 2023  1 year ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer